drugset / Trial / NCT00215423

Study in Patients With COPD

NCT00215423

Phase 2 Completed 49 enrolled Dey
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine which dose of the investigational drug is the most safe and effective for the treatment of COPD compared to the control drug

Timeline

Start
Primary completion
2003-12
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Formoterol Other / unclassified 2.5 ug Inhaled
Subject Formoterol Other / unclassified 5 ug Inhaled
Subject Formoterol Other / unclassified 10 ug Inhaled
Subject Formoterol Other / unclassified 12 ug Inhaled
Subject Formoterol Other / unclassified 20 ug Inhaled
Subject Formoterol Other / unclassified 40 ug Inhaled